administered in the presence or not of a pharmaceutically accepted adjuvant.

5. Claims 17-20, 22-24 and 26, drawn to an immunogenic composition comprising VEGFR3 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant.

6. Claims 17-24 and 26, drawn to an immunogenic composition comprising oligonucleotide encoding VEGFR3 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant.

7. Claim 25, drawn to an immunogenic composition comprising VEGF polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant.

8. Claims 25 and 26, drawn to an immunogenic composition comprising oligonucleotides encoding VEGF polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant.

9. Claim 27, drawn to an immunogenic composition comprising VEGF and at least one specific molecule oligonucleotide encoding VEGFR1 polypeptides, administered in the presence or not of a pharmaceutically accepted adjuvant.

10. Claim 27, drawn to an immunogenic composition comprising VEGF and at least one specific molecule oligonucleotide encoding VEGFR2 polypeptides, administered in the presence or not of a pharmaceutically accepted adjuvant.

11. Claim 27, drawn to an immunogenic composition comprising VEGF and at least one specific molecule oligonucleotide encoding VEGFR3 polypeptides, administered in the presence or not of a pharmaceutically accepted adjuvant.

12. Claim 27, drawn to an immunogenic composition comprising VEGF and at least one specific molecule oligonucleotide encoding NRP-1 polypeptides, administered in the presence or not of a pharmaceutically accepted adjuvant.

13. Claim 27, drawn to an immunogenic composition comprising VEGF and at least one specific molecule oligonucleotide encoding NRP-2 polypeptides, administered in the presence or not of a pharmaceutically accepted adjuvant.

14. Claim 27, drawn to an immunogenic composition comprising VEGF and at least one specific molecule VEGFR3 polypeptides, administered in the presence or not of a pharmaceutically accepted adjuvant.

15. Claim 27, drawn to an immunogenic composition comprising VEGF and at least one specific molecule NPR-1 polypeptides, administered in the presence or not of a pharmaceutically accepted adjuvant.

16. Claim 27, drawn to an immunogenic composition comprising VEGF and at least one specific molecule NRP-2 polypeptides, administered in the presence or not of a pharmaceutically accepted adjuvant.

17. Claims 28 and 29, drawn to an immunogenic composition comprising a bi-cistronic vector coding for VEGFR1 or fragment thereof and a mutant of VEGF, and a DNA vector coding for VEGFR1 or fragment thereof and a DNA vector coding for a mutant of VEGF, administered in the presence of or incorporated into Neisseria menigitidis outer membrane derived VSSP.

18. Claim 30, drawn to an immunogenic composition comprising a fusion protein containing a VEGFR1 or fragments thereof and a mutant of VEGF, administered in the presence of or incorporated into Neisseria meningitidis outer membrane derived VSSP.

19. Claims 27 and 31, drawn to an immunogenic composition comprising a VEGFR1 or fragments thereof and a mutant of VEGF, administered in the presence of or incorporated into Neisseria meningitidis outer membrane derived VSSP.

20. Claims 32 and 33, drawn to an immunogenic composition comprising a bi-cistronic

vector coding for VEGFR2 or fragment thereof and a mutant of VEGF, administered in the presence of or incorporated into Neisseria menigitidis outer membrane derived VSSP or an immunogenic composition comprising a DNA vector coding for VEGFR2 or fragment thereof and a DNA vector coding for a mutant of VEGF, administered in the presence of or incorporated into Neisseria menigitidis outer membrane derived VSSP.

21. Claim 34, drawn to an immunogenic composition comprising a fusion protein containing a VEGFR2 or fragments thereof and a mutant of VEGF, administered in the presence of or incorporated into Neisseria meningitidis outer membrane derived VSSP.

22. Claims 27 and 35, drawn to an immunogenic composition comprising a VEGFR2 or fragments thereof and a mutant of VEGF, administered in the presence of or incorporated into Neisseria meningitidis outer membrane derived VSSP.

23. Claims 36-39, 41-43, 61-62, 80, and 83-84, drawn to a method for active vaccination comprising administering an immunogenic composition comprising VEGFR1 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

24. Claims 36-43, 61-62, 80 and 83-84, drawn to a method for active vaccination comprising administering an immunogenic composition comprising oligonucleotides encoding VEGFR1 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

25. Claims 44-47, 49-51, 61-62, 81 and 83-84, drawn to a method for active vaccination comprising administering an immunogenic composition comprising VEGFR2 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an

increment of angiogenesis.

26. Claims 44-51, 61-62, 81 and 83-84, drawn to a method for active vaccination comprising administering an immunogenic composition comprising oligonucleotides encoding VEGFR2 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

27. Claims 52-55, 57-59, 61-62 and 82-84, drawn to a method for active vaccination comprising administering an immunogenic composition comprising VEGFR3 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

28. Claims 52-59, 61-62, and 82-84, drawn to a method for active vaccination comprising administering an immunogenic composition comprising oligonucleotides encoding VEGFR3 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

29. Claims 52-55, 57-59, 61-61, and 82-84, drawn to a method for active vaccination comprising administering an immunogenic composition comprising NRP-1 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

30. Claims 52-59, 61-62 and 82-84, drawn to a method for active vaccination comprising administering an immunogenic composition comprising oligonucleotides encoding NRP-1 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

31. Claims 52-55, 57-59, 61-62 and 82-84, drawn to a method for active vaccination comprising administering an immunogenic composition comprising NRP-2 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

32. Claims 52-59, 61-62 and 82-84, drawn to a method for active vaccination comprising administering an immunogenic composition comprising oligonucleotides encoding NRP-2 polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

33. Claims 60 and 93, drawn to a method for active vaccination comprising administering an immunogenic composition comprising VEGF polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

34. Claims 60 and 93, drawn to a method for active vaccination comprising administering an immunogenic composition comprising oligonucleotides encoding VEGF polypeptides and fragments thereof, administered in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

35. Claims 63-64 and 85-86, drawn to a method for active vaccination comprising administering bi-cistronic vector coding for VEGFR2 or fragment thereof and a mutant of VEGF, and a DNA vector coding for VEGFR2 or fragment thereof and a DNA vector coding for a mutant of VEGF, administered in the presence of or incorporated into Neisseria menigitidis outer membrane derived VSSP administering in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

36. Claims 65 and 87, drawn to a method for active vaccination comprising administering a fusion protein containing VEGFR2 or fragment thereof and a mutant of VEGF, administered in the presence of or incorporated into Neisseria menigitidis outer membrane derived VSSP administering in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

37. Claims 66 and 88, drawn to a method for active vaccination comprising administering an immunogenic protein composition comprising VEGFR2 or fragment thereof and a mutant of VEGF, administered in the presence of or incorporated into Neisseria menigitidis outer membrane derived VSSP administering in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

38. Claims 67-68, 89-90, and 94-95, drawn to a method for active vaccination comprising administering bi-cistronic vector coding for VEGFR1 or fragment thereof and a mutant of VEGF, and a DNA vector coding for VEGFR1 or fragment thereof and a DNA vector coding for a mutant of VEGF, administered in the presence of or incorporated into Neisseria menigitidis outer membrane derived VSSP administering in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

39. Claims 69, 91, and 96, drawn to a method for active vaccination comprising administering a fusion protein containing VEGFR1 or fragment thereof and a mutant of VEGF, administered in the presence of or incorporated into Neisseria menigitidis outer membrane derived VSSP administering in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

40. Claims 70, 92 and 97, drawn to a method for active vaccination comprising administering an immunogenic protein composition comprising VEGFR1 or

fragment thereof and a mutant of VEGF, administered in the presence of or incorporated into Neisseria menigitidis outer membrane derived VSSP administering in the presence or not of a pharmaceutically accepted adjuvant for the treatment of disorders associated to an increment of angiogenesis.

In response to the Restriction Requirement, Applicants elect the claims of Group 22 (i.e., claims 27 and 35) without traverse.

Applicants reserve the right to pursue the remaining non-elected inventions in divisional applications.

It is now believed that this application is in condition for further consideration and examination. If resolution of any remaining issues is required prior to examination of the application, it is respectfully requested that the Examiner contact Applicants' agent at the telephone number provided below.

Respectfully submitted,

Anna C. Chau
Registration No.: 54,637
Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
ACC:jp

235507_1